Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial
Summary: Background: Nanocovax is a recombinant severe acute respiratory syndrome coronavirus 2 subunit vaccine composed of full-length prefusion stabilized recombinant SARS-CoV-2 spike glycoproteins (S-2P) and aluminium hydroxide adjuvant. Methods: We conducted a dose-escalation, open label trial (...
-д хадгалсан:
Үндсэн зохиолчид: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Формат: | Ном |
Хэвлэсэн: |
Elsevier,
2022-07-01T00:00:00Z.
|
Нөхцлүүд: | |
Онлайн хандалт: | Connect to this object online. |
Шошгууд: |
Шошго нэмэх
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|
Интернэт
Connect to this object online.3rd Floor Main Library
Зохиогчийн тэмдэгт: |
A1234.567 |
---|---|
Хуулбар 1 | Бэлэн |